利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.046 秒)

    Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
    21.
    发明申请
    Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease 有权
    可溶性HER2和HER3剪接变体蛋白，剪接切换寡核苷酸及其在治疗疾病中的应用

    公开(公告)号：US20090105139A1

    公开(公告)日：2009-04-23

    申请号：US12157094

    申请日：2008-06-06

    申请人： Ryszard Kole ,  Peter Sazani ,  Jing Wan

    发明人： Ryszard Kole ,  Peter Sazani ,  Jing Wan

    IPC分类号： A61K38/16 ,  C07K14/00 ,  A61K31/7088 ,  A61K31/7105 ,  C12N15/11

    CPC分类号： C07K14/71 ,  A61K38/00

    摘要： Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of these splice variants, including splice switching oligonucleotides that modulate splicing of pre-mRNA that codes for these receptors.

    摘要翻译： 可溶性表皮生长因子受体2和3（HER2和HER3）剪接具有HER2和HER3拮抗剂活性和抗增殖性质的变体蛋白以及相应的核酸被用于治疗增殖性疾病，特别是癌症。 还提供了用于诱导这些剪接变体表达的组合物和方法，包括调节编码这些受体的前mRNA的剪接的剪接切换寡核苷酸。

    Tissue specific peptide conjugates and methods
    22.
    发明申请
    Tissue specific peptide conjugates and methods 审中-公开
    组织特异性肽缀合物和方法

    公开(公告)号：US20090099066A1

    公开(公告)日：2009-04-16

    申请号：US12217040

    申请日：2008-06-30

    申请人： Hong M. Moulton ,  Patrick L. Iversen

    发明人： Hong M. Moulton ,  Patrick L. Iversen

    IPC分类号： A61K38/14 ,  A61K38/10

    CPC分类号： C12N15/87 ,  C07K2319/33 ,  C12N2810/40

    摘要： Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the group consisting of RXR, RX, RB, and RBR; where R is arginine, B is β-alanine, and each X is independently —C(O)—(CHR1)n—NH—, where n is 4-6 and each R1 is independently H or methyl, such that at most two R1's are methyl. In one embodiment, X is a 6-aminohexanoic acid residue.

    摘要翻译： 可用于将治疗化合物靶向选定的哺乳动物组织的细胞穿透肽，其鉴定方法，形成含有此类肽的缀合物的方法和由此形成的缀合物。 细胞穿透肽的长度为8至30个氨基酸残基并由选自RXR，RX，RB和RBR的子序列组成; 其中R是精氨酸，B是β-丙氨酸，每个X独立地是-C（O） - （CHR 1）n -NH-，其中n是4-6，并且每个R 1独立地是H或甲基，使得至多两个 R1是甲基。 在一个实施方案中，X是6-氨基己酸残基。

    PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD
    24.
    发明申请
    PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD 有权
    肽联合，非取代的抗原寡聚化合物和方法

    公开(公告)号：US20080182973A1

    公开(公告)日：2008-07-31

    申请号：US12060135

    申请日：2008-03-31

    申请人： Patrick L. Iversen ,  Dwight D. Weller ,  Jed N. Hassinger

    发明人： Patrick L. Iversen ,  Dwight D. Weller ,  Jed N. Hassinger

    IPC分类号： C07K14/00 ,  C07H1/00

    CPC分类号： C12N15/113 ,  A61K48/0008 ,  C12N15/111 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/3145 ,  C12N2310/3233 ,  C12N2310/331 ,  C12N2310/3513 ,  C12N2320/32

    摘要： A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine for guanine substitutions.

    摘要翻译： 公开了治疗性低聚物 - 肽缀合物和使用该缀合物的方法。 缀合物包括（a）具有碱基序列的基本上不带电的寡核苷酸类似物化合物，其碱基序列包括与化合物所要结合的靶核酸区域中的四个或更多个连续胞嘧啶碱基互补的碱基序列，和（b ），富含精氨酸的肽有效地增强化合物进入靶细胞的摄取。 所述化合物中的碱基串包括位于所述串中的至少一个肌苷碱基，以将所述串中的连续鸟嘌呤碱基的数量限制为三个或更少。 通过富含精氨酸的肽，缀合物比单独的化合物具有更大的细胞摄取，并且在不存在肌苷用于鸟嘌呤取代的情况下，具有比缀合物更大的反义活性。

    Antisense antiviral compound and method for treating influenza viral infection
    27.
    发明授权
    Antisense antiviral compound and method for treating influenza viral infection 有权
    反义抗病毒化合物及治疗流感病毒感染的方法

    公开(公告)号：US08357664B2

    公开(公告)日：2013-01-22

    申请号：US11259434

    申请日：2005-10-25

    申请人： David A. Stein ,  Qing Ge ,  Jianzhu Chen ,  Patrick L. Iversen ,  Hong M. Moulton

    发明人： David A. Stein ,  Qing Ge ,  Jianzhu Chen ,  Patrick L. Iversen ,  Hong M. Moulton

    IPC分类号： A61K48/00

    CPC分类号： C12N15/1131 ,  C12N2310/3145 ,  C12N2310/3233 ,  C12N2310/3513

    摘要： The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3′ terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.

    摘要翻译： 本发明提供反义抗病毒化合物及其在抑制正粘病毒科的病毒生长和用于病毒感染治疗中的用途和生产方法。 该化合物特别可用于治疗哺乳动物的流感病毒感染。 反义抗病毒化合物是具有1）核酸酶抗性主链，2）12-40个核苷酸碱基的基本上不带电荷的吗啉代寡核苷酸，和3）长度为至少12个碱基的靶向序列与选自以下的靶区域杂交： ）流感病毒A，流感病毒B和流感病毒C的负义病毒RNA片段的5'或3'末端25个碱基; b）正义cRNA的3'末端的末端25个碱基; 和c）围绕流感病毒mRNA的AUG起始密码子的50个碱基。

    ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION
    28.
    发明申请
    ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION 有权
    抗真菌化合物和治疗FILOVIRUS感染的方法

    公开(公告)号：US20130011420A1

    公开(公告)日：2013-01-10

    申请号：US13469892

    申请日：2012-05-11

    申请人： Patrick L. Iversen ,  Dwight D. Weller

    发明人： Patrick L. Iversen ,  Dwight D. Weller

    IPC分类号： C07H21/00 ,  A61K39/00 ,  A61P31/12 ,  A61K48/00

    CPC分类号： C12N15/113 ,  A61K31/675 ,  A61K31/713 ,  C12N15/1131 ,  C12N2310/11 ,  C12N2310/3233

    摘要： The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof

    摘要翻译： 本发明提供反义抗病毒化合物，组合物及其使用和生产方法，主要用于抑制丝状病毒科病毒的复制，包括埃博拉病毒和马尔堡病毒。 化合物，组合物和方法还涉及治疗包括埃博拉和马尔堡病毒在内的哺乳动物中的病毒感染。 反义抗病毒化合物包括具有核酸酶抗性主链的磷酸二亚胺吗啉代寡核苷酸（PMOplus），约15-40个核苷酸碱基，至少两个但通常不超过一半的含哌嗪的亚单位间连接，以及针对AUG起始靶向序列 埃博拉病毒VP35的位点区域，埃博拉病毒VP24，马尔堡病毒VP24或马尔堡病毒NP，包括其组合和混合物

    ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION
    30.
    发明申请
    ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION 有权
    抗真菌化合物和治疗流感病毒感染的方法

    公开(公告)号：US20110118334A1

    公开(公告)日：2011-05-19

    申请号：US12945081

    申请日：2010-11-12

    申请人： Patrick L. Iversen

    发明人： Patrick L. Iversen

    IPC分类号： A61K31/7052 ,  C07H21/00 ,  C12N7/06 ,  A61P31/12

    CPC分类号： C07F9/65616 ,  A61K31/165 ,  A61K31/43 ,  A61K31/5377 ,  A61K31/545 ,  A61K31/7056 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  C12N15/113 ,  C12N15/1131 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/3513 ,  C12N2310/3521

    摘要： The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing.

    摘要翻译： 本发明涉及反义抗病毒化合物及其在抑制正粘病毒科的病毒生长和用于病毒感染治疗中的用途和生产方法。 该化合物特别可用于治疗哺乳动物的流感病毒感染。 示例性的反义抗病毒化合物是基本上不带电荷或部分带正电荷的吗啉代寡核苷酸，其具有1）核酸酶抗性主链，2）12-40个核苷酸碱基，和3）与目标区域杂交的至少12个碱基长度的靶向序列 选自以下：a）流感病毒A，流感病毒B和流感病毒C的阴性病毒RNA片段的5'或3'末端25个碱基; b）阳性vcRNA的5'或3'末端的末端30个碱基; c）流感病毒mRNA的AUG起始密码子周围的45个碱基; d）围绕可变剪接的流感mRNA的剪接供体或受体位点周围的50个碱基。